Central Nervous System News and Research

RSS

Weight loss drugs may reduce binge eating disorder symptoms

Drugs commonly used for weight loss, known as GLP-1 receptor agonists, have been found to reduce the key symptoms of binge eating disorder, in a new review of evidence led by University College London (UCL) researchers.

15 Jul 2026

GLP-1 receptor activation linked to lower depression and bipolar disorder odds

Genetic analyses linked BMI-related GLP-1 receptor activation to better mental well-being and lower odds of major depressive disorder and bipolar disorder. The findings do not prove that GLP-1 receptor agonist drugs treat psychiatric conditions, and randomized clinical trials are still needed.

15 Jul 2026

Study shows postoperative nerve blocks do not cause hyper-sensitization

Nerve blocks – local anesthetic injections that block pain signals – are a valuable opioid-sparing technique for controlling pain after surgery.

14 Jul 2026

EpilepsyGTx partners with ClearPoint Neuro to support targeted delivery of lead gene therapy in epilepsy

EpilepsyGTx, a biotechnology company developing cutting-edge gene therapies to treat refractory epilepsy, and ClearPoint Neuro ("ClearPoint"), a global therapy-enabling company offering precise navigation and delivery to the brain, today announced a partnership to support the targeted delivery of EpilepsyGTx's lead gene therapy candidate, EPY201, for focal refractory epilepsy (FRE).

From EpilepsyGTx 14 Jul 2026

Gut microbiota may shape eating behavior and guide new obesity treatments

The review shows how gut microbiota may influence appetite, food reward, inflammation, and energy balance through the gut-brain axis. Microbiota-targeted approaches could support future treatments for obesity and eating disorders, but clinical evidence remains limited.

12 Jul 2026

Discovery could pave the way for future vaccines against genital herpes

Researchers at the University of Gothenburg have identified a key protein that allows the virus that causes genital herpes to get into the nervous system.

9 Jul 2026

Study links PTSD to accelerated biological aging and chronic disease

Post-Traumatic Stress Disorder (PTSD) remains a common condition affecting World Trade Center (WTC) responders 25 years after the attack on the Twin Towers.

8 Jul 2026

Beckman Coulter Diagnostics expands Alzheimer’s portfolio with CE-marked p-Tau217 blood test and new high-specificity research assay

Beckman Coulter Diagnostics, a global leader in clinical diagnostics and a Danaher company, today announced it received CE Mark under IVDR for its Access p-Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of cognitive decline.

7 Jul 2026

New viral insights lay foundation for treating infection with JC polyomaviruses

In people with severely compromised immune systems, the JC polyomavirus can trigger a currently untreatable, usually fatal brain disease.

6 Jul 2026

BCG vaccine may remodel the human brain's immune environment

New research led by Mass General Brigham investigators suggests that the Bacillus Calmette-Guérin (BCG) vaccine - which is delivered through the skin to prevent tuberculosis - may remodel the human brain's immune environment, offering a potential biological explanation for previously observed associations between BCG vaccination and lower Alzheimer's disease risk.

6 Jul 2026

First-in-human trial tests safer T-cell therapy for pediatric brain cancers

Researchers report encouraging early results from a first-in-human clinical trial led by Children's National using a new T-cell immunotherapy for children and young adults with some of the deadliest brain tumors, including diffuse intrinsic pontine glioma (DIPG) and relapsed central nervous system (CNS) tumors.

30 Jun 2026

Duke engineers grow retinal blood vessel cells from pluripotent stem cells

Biomedical engineers at Duke University have used induced pluripotent stem cells (iPSCs) to grow specialized blood vessel cells critical to retinal health for the first time.

30 Jun 2026

Simple blood test could identify the most effective obesity drug

Fasting blood tests measuring GLP-1 and GIP levels may predict obesity treatment response to semaglutide and tirzepatide, enhancing personalized therapy.

29 Jun 2026

Study links COVID-19 to higher sleep apnea risk years after infection

Researchers analyzed more than 910,000 adults and found that SARS-CoV-2 infection was associated with a higher adjusted risk of new-onset obstructive sleep apnea up to 4.5 years later. The association appeared in both hospitalized and non-hospitalized COVID-19 patients, supporting targeted screening in higher-risk post-COVID groups while highlighting the need for objective sleep testing.

24 Jun 2026

Sugar-coated nanoparticles extend survival in aggressive glioblastoma mouse model

Researchers at Oregon State University have potentially found a new way to treat the most aggressive form of brain cancer, glioblastoma, whose two-year survival rate is less than 30%.

23 Jun 2026

Insilico and SK Biopharmaceuticals partner to develop AI-driven neuroimmune therapies

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research, development, and commercialization worldwide, announced a research and development collaboration at the BIO 2026 International Convention to discover AI-enabled innovative drug candidates in the neuroimmune area of the central nervous system.

22 Jun 2026

Study links neuroimmune dysregulation to complex fibromyalgia symptoms

Fibromyalgia is a complex disorder characterized primarily by chronic widespread pain, fatigue and other physical and cognitive symptoms.

22 Jun 2026

Pheno Therapeutics granted FDA IND clearance for lead multiple sclerosis therapeutic candidate PTD802

Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PTD802, the Company's lead therapeutic candidate.

From Pheno Therapeutics 22 Jun 2026

Scientists develop wearable robotic system to restore hand function

Researchers at the Medical University of Vienna, in collaboration with ETH Zurich, the Technical University of Munich and Medical Faculty Belgrade, have developed a wearable neurorobotic system that combines electrical neurostimulation with hand exoskeletons.

19 Jun 2026

Zebrafish study links altered neuronal genes to hyperarousal states

The altered presence of tiny fragments of neuronal genes, called microexons, causes hyperarousal in zebrafish. This is the main conclusion of an international study led by the Pompeu Fabra University (UPF) and the Centre for Genomic Regulation (CRG).

19 Jun 2026